[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Poised for Higher Valuation on Povetacicept, Cystic Fibrosis Pipeline, RBC Says",
    "summary": "Vertex Pharmaceuticals' (VRTX) near-term data cementing the bright prospects of investigational drug",
    "url": "https://finnhub.io/api/news?id=0be902895ec6a824908ac05a6ee3d810b8dc29f5833167276cc4345d172d1f0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769098677,
      "headline": "Vertex Pharmaceuticals Poised for Higher Valuation on Povetacicept, Cystic Fibrosis Pipeline, RBC Says",
      "id": 138205927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals' (VRTX) near-term data cementing the bright prospects of investigational drug",
      "url": "https://finnhub.io/api/news?id=0be902895ec6a824908ac05a6ee3d810b8dc29f5833167276cc4345d172d1f0a"
    }
  },
  {
    "ts": null,
    "headline": "Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX)",
    "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers.",
    "url": "https://finnhub.io/api/news?id=f36d8bb8b2b0ebf32e48aece94196c9b9783b83f45e3a9412bd2eb4ed1c74e39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769052944,
      "headline": "Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX)",
      "id": 138213381,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers.",
      "url": "https://finnhub.io/api/news?id=f36d8bb8b2b0ebf32e48aece94196c9b9783b83f45e3a9412bd2eb4ed1c74e39"
    }
  },
  {
    "ts": null,
    "headline": "Is Bullish CF Analyst Sentiment Reframing the Pipeline Risk Narrative for Vertex Pharmaceuticals (VRTX)?",
    "summary": "In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, both citing confidence in the company’s core cystic fibrosis business and upcoming clinical data readouts in 2026–2027. This cluster of positive analyst views has sharpened investor focus on how Vertex’s cystic fibrosis franchise underpins its broader pipeline ambitions and risk profile. We’ll now look at how this wave of bullish analyst commentary around Vertex’s cystic...",
    "url": "https://finnhub.io/api/news?id=b4f09f1bdb822fd5518ba812ace33c5c449241d45ff5b802041fcdc3e7d3a9f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769041528,
      "headline": "Is Bullish CF Analyst Sentiment Reframing the Pipeline Risk Narrative for Vertex Pharmaceuticals (VRTX)?",
      "id": 138200232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, both citing confidence in the company’s core cystic fibrosis business and upcoming clinical data readouts in 2026–2027. This cluster of positive analyst views has sharpened investor focus on how Vertex’s cystic fibrosis franchise underpins its broader pipeline ambitions and risk profile. We’ll now look at how this wave of bullish analyst commentary around Vertex’s cystic...",
      "url": "https://finnhub.io/api/news?id=b4f09f1bdb822fd5518ba812ace33c5c449241d45ff5b802041fcdc3e7d3a9f2"
    }
  }
]